无管路贴敷式自动胰岛素输注系统在儿童和成人1型糖尿病中的多中心试验
这项单臂、多中心、前瞻性研究纳入112名儿童(6-13.9岁)和129名成人(14-70岁)1型糖尿病患者,先进行2周标准治疗,随后进行3个月自动胰岛素输注。结果显示儿童HbA1c降低0.71%,成人降低0.38%,目标血糖范围内时间分别增加15.6%和9.3%,严重低血糖和糖尿病酮症酸中毒发生率低。
要点
- 无管路贴敷式自动胰岛素输注系统可安全用于儿童和成人1型糖尿病。
- 儿童HbA1c降低0.71%,成人降低0.38%,均具统计学显著性。
- 目标血糖范围内时间儿童增加15.6%,成人增加9.3%,低血糖发生率低。
核心结论
- 无管路自动胰岛素输注系统安全,能显著改善儿童和成人1型糖尿病患者的HbA1c和目标血糖范围内时间,且低血糖发生率极低。
研究设计与样本
- 单臂、多中心、前瞻性研究,纳入112名儿童(6-13.9岁)和129名成人(14-70岁)1型糖尿病患者,先进行2周标准治疗,随后进行3个月自动胰岛素输注。
主要发现
- 儿童HbA1c降低0.71%(7.8 mmol/mol)(从7.67±0.95%降至6.99±0.63%[60±10.4 mmol/mol降至53±6.9 mmol/mol],P<0.0001)。
- 成人HbA1c降低0.38%(4.2 mmol/mol)(从7.16±0.86%降至6.78±0.68%[55±9.4 mmol/mol降至51±7.4 mmol/mol],P<0.0001)。
- 儿童目标范围内时间(70-180 mg/dL)增加15.6±11.5%(每天3.7小时),成人增加9.3±11.8%(每天2.2小时)(均P<0.0001)。
- 成人低血糖时间(<70 mg/dL)中位数从2.00%[0.63, 4.06]降至1.09%[0.46, 1.75](P<0.0001),儿童该参数保持不变。
- 发生3例严重低血糖事件(非自动胰岛素输注故障所致)和1例糖尿病酮症酸中毒事件(输注部位故障所致)。
临床怎么用
- 对于儿童和成人1型糖尿病患者,可考虑使用无管路贴敷式自动胰岛素输注系统以改善血糖控制并降低低血糖风险。
局限性
- 研究为单臂设计,缺乏随机对照,样本量有限,随访时间较短(3个月),可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Advances in diabetes technology have transformed the treatment paradigm for type 1 diabetes, yet the burden of disease is significant. We report on a pivotal safety study of the first tubeless, on-body automated insulin delivery system with customizable glycemic targets. RESEARCH DESIGN AND METHODS: This single-arm, multicenter, prospective study enrolled 112 children (age 6-13.9 years) and 129 adults (age 14-70 years). A 2-week standard therapy phase (usual insulin regimen) was followed by 3 months of automated insulin delivery. Primary safety outcomes were incidence of severe hypoglycemia and diabetic ketoacidosis. Primary effectiveness outcomes were change in HbA1c and percent time in sensor glucose range 70-180 mg/dL ("time in range"). RESULTS: A total of 235 participants (98% of enrolled, including 111 children and 124 adults) completed the study. HbA1c was significantly reduced in children by 0.71% (7.8 mmol/mol) (mean ± SD: 7.67 ± 0.95% to 6.99 ± 0.63% [60 ± 10.4 mmol/mol to 53 ± 6.9 mmol/mol], P < 0.0001) and in adults by 0.38% (4.2 mmol/mol) (7.16 ± 0.86% to 6.78 ± 0.68% [55 ± 9.4 mmol/mol to 51 ± 7.4 mmol/mol], P < 0.0001). Time in range was improved from standard therapy by 15.6 ± 11.5% or 3.7 h/day in children and 9.3 ± 11.8% or 2.2 h/day in adults (both P < 0.0001). This was accomplished with a reduction in time in hypoglycemia <70 mg/dL among adults (median [interquartile range]: 2.00% [0.63, 4.06] to 1.09% [0.46, 1.75], P < 0.0001), while this parameter remained the same in children. There were three severe hypoglycemia events not attributable to automated insulin delivery malfunction and one diabetic ketoacidosis event from an infusion site failure. CONCLUSIONS: This tubeless automated insulin delivery system was safe and allowed participants to significantly improve HbA1c levels and time in target glucose range with a very low occurrence of hypoglycemia.
引用
- Brown SA, Forlenza GP, Bode BW, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021. PMID: 34099518. doi:10.2337/dc21-0172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。